Treatment of immune thrombocytopenia in Australian adults: A multicenter retrospective observational study

CONCLUSION: A wide range of "second-line" agents were used across centers with variable response rates and side effect profiles. Findings suggest greater effectiveness of rituximab and TPO-A, supporting their use earlier in the treatment course of patients with ITP across Australia.PMID:36186101 | PMC:PMC9483174 | DOI:10.1002/rth2.12792

Source: Thrombosis and Haemostasis - October 3, 2022 Category: Hematology Authors: Adam Rosenberg Catelyn Cashion Fariya Ali Harini Haran Raaj K Biswas Vivien Chen Helen Crowther Jennifer Curnow Elyssa Deakin Chee-Wee Tan Yi Ling Tan Andrew Vanlint Christopher M Ward Robert Bird David J Rabbolini Source Type: research